



Johnson & Johnson Reports 2009 Third-Quarter Results:

Sales of \$15.1 Billion Decreased 5.3% Versus 2008 Third Quarter EPS of \$1.20 increased 2.6% Versus 2008 Third Quarter

NEW BRUNSWICK, N.J., Oct 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of \$15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

Net earnings and diluted earnings per share for the third quarter of 2009 were \$3.3 billion and \$1.20, respectively, representing increases of 1.1% and 2.6%, as compared to the same period in 2008. The Company raised its earnings guidance for full-year 2009 to \$4.54 - \$4.59 per share, which excludes the impact of special items.

"We continue to successfully manage our broad base of businesses and deliver solid earnings despite the impact of patent expirations and the challenges posed by the current economic environment," said William C. Weldon, Chairman and Chief Executive Officer. "We completed multiple acquisitions and strategic collaborations and received several new product approvals in the quarter that will benefit patients worldwide and drive future growth."

Worldwide Consumer sales of \$4.0 billion for the third quarter represented a decrease of 2.7% versus the prior year with an increase of 1.1% operationally and a negative impact from currency of 3.8%. Domestic sales decreased 4.4%; international sales decreased 1.4%, which reflected an operational increase of 5.2% and a negative currency impact of 6.6%.

Contributing to operational sales growth during the quarter were sales of Dabao skin care products; AVEENO® skin care products; SPLENDA® No Calorie Sweetener; Le Petit Marseillais® beauty care products; and LISTERINE® antiseptic mouthrinse. Other growth drivers were sales from the acquisition of Vania Expansion SNC.

Worldwide Pharmaceutical sales of \$5.3 billion for the third quarter represented a decrease of 14.1% versus the prior year with an operational decline of 11.9% and a negative impact from currency of 2.2%. Domestic sales decreased 19.2%; international sales decreased 7.1%, which reflected an operational decrease of 1.9% and a negative currency impact of 5.2%.

REMICADE® (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases, demonstrated solid sales performance during the quarter. Several other pharmaceutical products had strong growth including PREZISTA® (darunavir), a treatment for HIV; VELCADE® (bortezomib), a treatment for multiple myeloma; and RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment, an antipsychotic medication. Sales results of TOPAMAX® (topiramate), an antiepileptic and a treatment for migraine, and RISPERDAL® (risperidone), an antipsychotic medication, were negatively impacted by generic competition.

During the quarter, the U.S. Food and Drug Administration (FDA) approved STELARA™ () (ustekinumab) for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. The FDA also approved INVEGA® SUSTENNA™ (paliperidone palmitate) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults; the first once-monthly, long-acting, injectable atypical antipsychotic approved in the U.S. for this use. In addition, the FDA approved the Supplemental New Drug Application for INVEGA® (paliperidone) extended-release tablets for the acute treatment of schizoaffective disorder either as monotherapy or adjunctive therapy to mood stabilizers and/or antidepressants.

On Oct. 6, the European Commission approved SIMPONI™ (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderate-to-severe, active rheumatoid arthritis, active and progressive psoriatic arthritis and severe, active ankylosing spondylitis.

During the quarter, the Company completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program as well as an equity investment in Elan. Additionally, the Company announced that it had entered into a licensing and collaboration agreement with Gilead Sciences, Inc., for the development and commercialization of a new fixed dose combination of investigational compound TMC278 (rilpivirine hydrochloride 25 mg) and Gilead's TRUVADA® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) for treatment-naïve adult patients with HIV-1.

Early in the fourth quarter, the Company announced that it had entered into a strategic collaboration with Crucell, N.V., focusing on the discovery, development and commercialization of monoclonal antibodies and vaccines for the treatment and prevention of influenza and other infectious and non-infectious diseases. The agreement also included an 18% equity investment in Crucell, N.V.

Worldwide Medical Devices and Diagnostics sales of \$5.8 billion for the third quarter represented an increase of 2.3% versus the prior year with an operational increase of 4.1% and a negative currency impact of 1.8%. Domestic sales increased 4.5%; international sales increased 0.5%, which reflected an operational increase of 3.8% and a negative currency impact of 3.3%.

Primary contributors to the operational growth included Ethicon's surgical care and aesthetics products; Ethicon Endo-Surgery's minimally invasive products; DePuy's orthopaedic joint reconstruction, spine, and sports medicine businesses; and Ortho-Clinical Diagnostics' professional products. This growth was partially offset by lower sales in the Cordis franchise, reflecting strong competition in the drug-eluting stent market, and the 2008 divestiture of the Professional Wound Care products in our Ethicon business.

About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 117,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

NOTE TO INVESTORS

Johnson & Johnson will conduct a meeting with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. The schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson can be found on the Company's website at www.jnj.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

THIRD QUARTER

	2009	2008	Total	Percent Change	
				Operations	Currency
Sales to customers by segment of business					
Consumer					
U.S.	\$1,691	1,769	(4.4)%	(4.4)	-
International	2,298	2,330	(1.4)	5.2	(6.6)

-----	3,989	4,099	(2.7)	1.1	(3.8)
-----	-----	-----	-----	-----	-----
Pharmaceutical					
U.S.	2,857	3,538	(19.2)	(19.2)	-
International	2,392	2,575	(7.1)	(1.9)	(5.2)
-----	-----	-----	-----	-----	-----
	5,249	6,113	(14.1)	(11.9)	(2.2)
-----	-----	-----	-----	-----	-----
Med Devices & Diagnostics					
U.S.	2,766	2,648	4.5	4.5	-
International	3,077	3,061	0.5	3.8	(3.3)
-----	-----	-----	-----	-----	-----
	5,843	5,709	2.3	4.1	(1.8)
-----	-----	-----	-----	-----	-----
U.S.	7,314	7,955	(8.1)	(8.1)	-
International	7,767	7,966	(2.5)	2.4	(4.9)
-----	-----	-----	-----	-----	-----
Worldwide	\$15,081	15,921	(5.3)%	(2.8)	(2.5)
-----	-----	-----	-----	-----	-----

(Unaudited; Dollars in Millions)

NINE MONTHS

-----	2009	2008	Total	Percent Change	
-----	-----	-----	-----	Operations	Currency
-----	-----	-----	-----	-----	-----
Sales to customers by segment of business					
Consumer					
U.S.	\$5,125	5,282	(3.0)%	(3.0)	-
International	6,429	6,917	(7.1)	4.1	(11.2)
-----	-----	-----	-----	-----	-----
	11,554	12,199	(5.3)	1.0	(6.3)
-----	-----	-----	-----	-----	-----
Pharmaceutical					
U.S.	9,703	11,401	(14.9)	(14.9)	-
International	6,824	7,481	(8.8)	1.4	(10.2)
-----	-----	-----	-----	-----	-----
	16,527	18,882	(12.5)	(8.5)	(4.0)
-----	-----	-----	-----	-----	-----
Med Devices & Diagnostics					
U.S.	8,194	7,959	3.0	3.0	-
International	9,071	9,525	(4.8)	3.7	(8.5)
-----	-----	-----	-----	-----	-----
	17,265	17,484	(1.3)	3.3	(4.6)
-----	-----	-----	-----	-----	-----
U.S.	23,022	24,642	(6.6)	(6.6)	-
International	22,324	23,923	(6.7)	3.1	(9.8)
-----	-----	-----	-----	-----	-----
Worldwide	\$45,346	48,565	(6.6)%	(1.8)	(4.8)
-----	-----	-----	-----	-----	-----

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

THIRD QUARTER

	2009	2008	Total	Percent Change	
				Operations	Currency
Sales to customers by geographic area					
U.S.	\$7,314	7,955	(8.1)%	(8.1)	-
Europe	3,879	4,076	(4.8)	2.1	(6.9)
Western Hemisphere excluding U.S.	1,338	1,461	(8.4)	1.5	(9.9)
Asia-Pacific, Africa	2,550	2,429	5.0	3.5	1.5
International	7,767	7,966	(2.5)	2.4	(4.9)
Worldwide	\$15,081	15,921	(5.3)%	(2.8)	(2.5)

(Unaudited; Dollars in Millions)

NINE MONTHS

	2009	2008	Total	Percent Change	
				Operations	Currency
Sales to customers by geographic area					
U.S.	\$23,022	24,642	(6.6)%	(6.6)	-
Europe	11,522	12,931	(10.9)	1.2	(12.1)
Western Hemisphere excluding U.S.	3,615	3,986	(9.3)	5.8	(15.1)
Asia-Pacific, Africa	7,187	7,006	2.6	5.1	(2.5)
International	22,324	23,923	(6.7)	3.1	(9.8)
Worldwide	\$45,346	48,565	(6.6)%	(1.8)	(4.8)

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except
Per Share Figures)

THIRD QUARTER

	2009		2008		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$15,081	100.0	\$15,921	100.0	(5.3)
Cost of products sold	4,434	29.4	4,774	30.0	(7.1)
Selling, marketing and administrative expenses	4,767	31.6	5,195	32.6	(8.2)
Research expense	1,617	10.7	1,861	11.7	(13.1)
Interest (income) expense, net	114	0.7	25	0.2	
Other (income) expense, net	(96)	(0.6)	(224)	(1.4)	
Earnings before provision for taxes on income	4,245	28.2	4,290	26.9	(1.0)
Provision for taxes on income	900	6.0	980	6.1	(8.2)
Net earnings	\$3,345	22.2	\$3,310	20.8	1.1
Net earnings per share (Diluted)	\$1.20		\$1.17		2.6
Average shares outstanding (Diluted)	2,793.0		2,831.3		
Effective tax rate	21.2%		22.8%		

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except
Per Share Figures)

NINE MONTHS

	2009		2008		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$45,346	100.0	\$48,565	100.0	(6.6)
Cost of products sold	13,135	29.0	14,139	29.1	(7.1)
Selling, marketing and administrative expenses	14,172	31.3	15,825	32.6	(10.4)
Research expense	4,773	10.5	5,469	11.3	(12.7)

In-process research & development	-	-	40	0.1	
Interest (income) expense, net	280	0.6	57	0.1	
Other (income) expense, net	(165)	(0.4)	(377)	(0.8)	
-----	-----	-----	-----	-----	-----
Earnings before provision for taxes on income	13,151	29.0	13,412	27.6	(1.9)
Provision for taxes on income	3,091	6.8	3,177	6.5	(2.7)
-----	-----	---	-----	---	-----
Net earnings	\$10,060	22.2	\$10,235	21.1	(1.7)
-----	-----	---	-----	-----	-----
Net earnings per share (Diluted)	\$3.61		\$3.60		0.3
Average shares outstanding (Diluted)	2,787.9		2,847.8		
Effective tax rate	23.5%		23.7%		

Adjusted earnings before provision for taxes and net earnings					
Earnings before provision for taxes on income	\$13,151	29.0	\$13,452 (1)	27.7	(2.2)
Net earnings	\$10,060	22.2	\$10,275 (1)	21.2	(2.1)
Net earnings per share (Diluted)	\$3.61		\$3.61 (1)		0.0
Effective tax rate	23.5%		23.6%		
-----	-----	-----	-----	-----	---

(1) The difference between as reported earnings and as adjusted earnings before provision for taxes on income and net earnings and net earnings per share (diluted) is IPR&D of \$40 million with no tax benefit and \$0.01 per share, respectively.

REPORTED SALES vs. PRIOR PERIOD (\$MM)

			THIRD QUARTER		

			% Change		

	2009	2008	Reported	Operational (1)	Currency
	-----	-----	-----	-----	-----
CONSUMER SEGMENT (2)					

SKIN CARE

US	370	358	3.4%	3.4%	-
Intl	472	500	-5.6%	-0.1%	-5.5%
WW	842	858	-1.9%	1.3%	-3.2%
BABY CARE					

US	102	114	-10.5%	-10.5%	-
Intl	442	472	-6.4%	-0.7%	-5.7%
WW	544	586	-7.2%	-2.6%	-4.6%
ORAL CARE					

US	187	204	-8.3%	-8.3%	-
Intl	223	230	-3.0%	4.8%	-7.8%
WW	410	434	-5.5%	-1.4%	-4.1%
OTC/NUTRITIONALS					

US	732	778	-5.9%	-5.9%	-
Intl	666	661	0.8%	8.0%	-7.2%
WW	1,398	1,439	-2.8%	0.5%	-3.3%
WOMEN'S HEALTH					

US	142	164	-13.4%	-13.4%	-
Intl	360	346	4.0%	11.7%	-7.7%
WW	502	510	-1.6%	3.6%	-5.2%
WOUND CARE / OTHER					

US	158	151	4.6%	4.6%	-
Intl	135	121	11.6%	18.0%	-6.4%
WW	293	272	7.7%	10.5%	-2.8%
TOTAL CONSUMER					

US	1,691	1,769	-4.4%	-4.4%	-
Intl	2,298	2,330	-1.4%	5.2%	-6.6%
WW	3,989	4,099	-2.7%	1.1%	-3.8%

NINE MONTHS

% Change

	2009	2008	Reported	Operational (1)	Currency

CONSUMER SEGMENT (2)					

SKIN CARE					

US	1,204	1,119	7.6%	7.6%	-
Intl	1,313	1,418	-7.4%	3.0%	-10.4%
WW	2,517	2,537	-0.8%	5.0%	-5.8%
BABY CARE					

US	308	340	-9.4%	-9.4%	-
Intl	1,233	1,351	-8.7%	0.7%	-9.4%

WW	1,541	1,691	-8.9%	-1.4%	-7.5%
ORAL CARE					

US	549	588	-6.6%	-6.6%	-
Intl	612	640	-4.4%	8.3%	-12.7%
WW	1,161	1,228	-5.5%	1.1%	-6.6%
OTC/NUTRITIONALS					

US	2,137	2,299	-7.0%	-7.0%	-
Intl	1,919	2,139	-10.3%	1.8%	-12.1%
WW	4,056	4,438	-8.6%	-2.8%	-5.8%
WOMEN'S HEALTH					

US	443	470	-5.7%	-5.7%	-
Intl	963	1,005	-4.2%	7.2%	-11.4%
WW	1,406	1,475	-4.7%	3.1%	-7.8%
WOUND CARE / OTHER					

US	484	466	3.9%	3.9%	-
Intl	389	364	6.9%	18.8%	-11.9%
WW	873	830	5.2%	10.5%	-5.3%
TOTAL CONSUMER					

US	5,125	5,282	-3.0%	-3.0%	-
Intl	6,429	6,917	-7.1%	4.1%	-11.2%
WW	11,554	12,199	-5.3%	1.0%	-6.3%

* See footnotes below

THIRD QUARTER

	2009	2008	% Change		
			Reported	Operational (1)	Currency
	----	----	-----	-----	-----
PHARMACEUTICAL SEGMENT (2)					

ACIPHEX/PARIET					

US	131	130	0.8%	0.8%	-
Intl	130	152	-14.5%	-9.0%	-5.5%
WW	261	282	-7.4%	-4.4%	-3.0%
CONCERTA					

US	205	190	7.9%	7.9%	-
Intl	79	208	-62.0%	-59.2%	-2.8%
WW	284	398	-28.6%	-27.2%	-1.4%
DURAGESIC/FENTANYL TRANSDERMAL					

US	38	54	-29.6%	-29.6%	-
Intl	168	205	-18.0%	-15.2%	-2.8%

WW	206	259	-20.5%	-18.3%	-2.2%
LEVAQUIN/FLOXIN					

US	294	313	-6.1%	-6.1%	-
Intl	17	20	-15.0%	0.3%	-15.3%
WW	311	333	-6.6%	-5.7%	-0.9%
PROCRIT/EPREX					

US	299	334	-10.5%	-10.5%	-
Intl	243	285	-14.7%	-9.6%	-5.1%
WW	542	619	-12.4%	-10.0%	-2.4%
RAZADYNE/REMINYL					

US	1	31	-96.8%	-96.8%	-
Intl	96	107	-10.3%	-3.8%	-6.5%
WW	97	138	-29.7%	-24.7%	-5.0%
REMICADE					

US	822	778	5.7%	5.7%	-
US Exports (4)	208	198	5.1%	5.1%	-
Intl	6	2	200.0%	198.7%	1.3%
WW	1,036	978	5.9%	5.9%	-
RISPERDAL/RISPERIDONE					

US	35	122	-71.3%	-71.3%	-
Intl	157	198	-20.7%	-21.4%	0.7%
WW	192	320	-40.0%	-40.4%	0.4%
RISPERDAL CONSTA					

US	129	118	9.3%	9.3%	-
Intl	224	220	1.8%	10.2%	-8.4%
WW	353	338	4.4%	9.9%	-5.5%
TOPAMAX					

US	72	606	-88.1%	-88.1%	-
Intl	103	122	-15.6%	-7.9%	-7.7%
WW	175	728	-76.0%	-74.7%	-1.3%
VELCADE					

US	-	1	-100.0%	-100.0%	-
Intl	231	189	22.2%	31.1%	-8.9%
WW	231	190	21.6%	30.5%	-8.9%
OTHER					

US	623	663	-6.0%	-6.0%	-
Intl	938	867	8.2%	13.6%	-5.4%
WW	1,561	1,530	2.0%	5.1%	-3.1%
TOTAL PHARMACEUTICAL					

US	2,857	3,538	-19.2%	-19.2%	-
Intl	2,392	2,575	-7.1%	-1.9%	-5.2%
WW	5,249	6,113	-14.1%	-11.9%	-2.2%

MAJOR NEW PHARM PRODUCTS (5)

PREZISTA

US	78	34	129.4%	129.4%	-
Intl	73	45	62.2%	77.0%	-14.8%
WW	151	79	91.1%	99.5%	-8.4%

INVEGA

US	61	73	-16.4%	-16.4%	-
Intl	36	16	125.0%	142.5%	-17.5%
WW	97	89	9.0%	12.3%	-3.3%

NINE MONTHS

% Change

	2009	2008	Reported	Operational (1)	Currency
--	------	------	----------	-----------------	----------

PHARMACEUTICAL SEGMENT (2)

ACIPHEX/PARIET

US	397	399	-0.5%	-0.5%	-
Intl	387	485	-20.2%	-9.3%	-10.9%
WW	784	884	-11.3%	-5.3%	-6.0%

CONCERTA

US	707	622	13.7%	13.7%	-
Intl	238	345	-31.0%	-20.8%	-10.2%
WW	945	967	-2.3%	1.3%	-3.6%

DURAGESIC/FENTANYL TRANSDERMAL

US	163	199	-18.1%	-18.1%	-
Intl	492	565	-12.9%	-4.3%	-8.6%
WW	655	764	-14.3%	-8.0%	-6.3%

LEVAQUIN/FLOXIN

US	1,045	1,117	-6.4%	-6.4%	-
Intl	53	63	-15.9%	1.4%	-17.3%
WW	1,098	1,180	-6.9%	-6.0%	-0.9%

PROCRIT/EXPRES

US	950	1,014	-6.3%	-6.3%	-
Intl	719	886	-18.8%	-9.0%	-9.8%
WW	1,669	1,900	-12.2%	-7.6%	-4.6%

RAZADYNE/REMINYL

US	30	123	-75.6%	-75.6%	-
Intl	275	316	-13.0%	-1.2%	-11.8%

WW	305	439	-30.5%	-22.0%	-8.5%
----	-----	-----	--------	--------	-------

REMICADE

US	2,330	2,138	9.0%	9.0%	-
US Exports (4)	821	718	14.3%	14.3%	-
Intl	15	6	150.0%	145.8%	4.2%
WW	3,166	2,862	10.6%	10.6%	-

RISPERDAL/RISPERIDONE

US	223	1,196	-81.4%	-81.4%	-
Intl	483	645	-25.1%	-21.3%	-3.8%
WW	706	1,841	-61.7%	-60.4%	-1.3%

RISPERDAL CONSTA

US	386	339	13.9%	13.9%	-
Intl	640	651	-1.7%	12.6%	-14.3%
WW	1,026	990	3.6%	13.0%	-9.4%

TOPAMAX

US	642	1,674	-61.6%	-61.6%	-
Intl	317	377	-15.9%	-3.5%	-12.4%
WW	959	2,051	-53.2%	-50.9%	-2.3%

VELCADE

US	-	4	-100.0%	-100.0%	-
Intl	652	575	13.4%	26.7%	-13.3%
WW	652	579	12.6%	25.8%	-13.2%

OTHER

US	2,009	1,858	8.1%	8.1%	-
Intl	2,553	2,567	-0.5%	9.2%	-9.7%
WW	4,562	4,425	3.1%	8.8%	-5.7%

TOTAL PHARMACEUTICAL

US	9,703	11,401	-14.9%	-14.9%	-
Intl	6,824	7,481	-8.8%	1.4%	-10.2%
WW	16,527	18,882	-12.5%	-8.5%	-4.0%

MAJOR NEW PHARM PRODUCTS (5)

PREZISTA

US	215	109	97.2%	97.2%	-
Intl	198	132	50.0%	70.0%	-20.0%
WW	413	241	71.4%	82.3%	-10.9%

INVEGA

US	194	192	1.0%	1.0%	-
Intl	93	39	138.5%	168.1%	-29.6%
WW	287	231	24.2%	29.2%	-5.0%

* See footnotes below

THIRD QUARTER

% Change

	2009	2008	Reported	Operational (1)	Currency
MEDICAL DEVICES AND DIAG (2) (3)					

CORDIS (6)					

US	233	259	-10.0%	-10.0%	-
Intl	407	431	-5.6%	-4.6%	-1.0%
WW	640	690	-7.2%	-6.6%	-0.6%
DEPUY					

US	740	698	6.0%	6.0%	-
Intl	544	533	2.1%	7.6%	-5.5%
WW	1,284	1,231	4.3%	6.7%	-2.4%
DIABETES CARE					

US	332	349	-4.9%	-4.9%	-
Intl	302	318	-5.0%	-0.4%	-4.6%
WW	634	667	-4.9%	-2.7%	-2.2%
ETHICON					

US	439	372	18.0%	18.0%	-
Intl	580	585	-0.9%	3.8%	-4.7%
WW	1,019	957	6.5%	9.4%	-2.9%
ETHICON ENDO-SURGERY					

US	499	473	5.5%	5.5%	-
Intl	607	569	6.7%	10.9%	-4.2%
WW	1,106	1,042	6.1%	8.4%	-2.3%
ORTHO-CLINICAL DIAGNOSTICS					

US	285	261	9.2%	9.2%	-
Intl	216	209	3.3%	7.0%	-3.7%
WW	501	470	6.6%	8.2%	-1.6%
VISION CARE					

US	238	236	0.8%	0.8%	-
Intl	421	416	1.2%	-0.2%	1.4%
WW	659	652	1.1%	0.2%	0.9%
TOTAL MEDICAL DEVICES AND DIAG					

US	2,766	2,648	4.5%	4.5%	-
Intl	3,077	3,061	0.5%	3.8%	-3.3%
WW	5,843	5,709	2.3%	4.1%	-1.8%

NINE MONTHS

	2009	2008	% Change		
			Reported	Operational (1)	Currency
MEDICAL DEVICES AND DIAG (2) (3)					

CORDIS (6)					

US	731	929	-21.3%	-21.3%	-
Intl	1,251	1,375	-9.0%	-3.9%	-5.1%
WW	1,982	2,304	-14.0%	-10.9%	-3.1%
DEPUY					

US	2,268	2,129	6.5%	6.5%	-
Intl	1,631	1,717	-5.0%	6.8%	-11.8%
WW	3,899	3,846	1.4%	6.7%	-5.3%
DIABETES CARE					

US	908	990	-8.3%	-8.3%	-
Intl	877	966	-9.2%	0.2%	-9.4%
WW	1,785	1,956	-8.7%	-4.1%	-4.6%
ETHICON					

US	1,296	1,087	19.2%	19.2%	-
Intl	1,717	1,835	-6.4%	3.6%	-10.0%
WW	3,013	2,922	3.1%	9.3%	-6.2%
ETHICON ENDO-SURGERY					

US	1,442	1,386	4.0%	4.0%	-
Intl	1,794	1,783	0.6%	10.6%	-10.0%
WW	3,236	3,169	2.1%	7.7%	-5.6%
ORTHO-CLINICAL DIAGNOSTICS					

US	846	749	13.0%	13.0%	-
Intl	616	640	-3.8%	4.8%	-8.6%
WW	1,462	1,389	5.3%	9.3%	-4.0%
VISION CARE					

US	703	689	2.0%	2.0%	-
Intl	1,185	1,209	-2.0%	0.3%	-2.3%
WW	1,888	1,898	-0.5%	0.9%	-1.4%
TOTAL MEDICAL DEVICES AND DIAG					

US	8,194	7,959	3.0%	3.0%	-
Intl	9,071	9,525	-4.8%	3.7%	-8.5%
WW	17,265	17,484	-1.3%	3.3%	-4.6%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Prior year amounts have been reclassified to conform with current presentation

- (4) For external purposes, reported as U.S. sales
- (5) Included in Other
- (6) Includes sales of Drug-Eluting Stents for Q3 2009 of \$53, \$158 and \$211MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for Q3 2008 of \$97, \$192 and \$289MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for September YTD 2009 of \$189, \$507 and \$696MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for September YTD 2008 of \$433, \$650 and \$1,083MM Domestic, International and Worldwide respectively

SOURCE Johnson & Johnson

<http://www.jnj.com>

Copyright © 2009 PR Newswire. All rights reserved